nach oben

Neurosurgical Review

Erschienen in:

18.06.2018 | Review

Progress in moyamoya disease

verfasst von: Shuling Shang, Da Zhou, Jingyuan Ya, Sijie Li, Qi Yang, Yuchuan Ding, Xunming Ji, Ran Meng

Erschienen in: Neurosurgical Review | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Moyamoya disease is characterized by progressive stenosis or occlusion of the intracranial portion of the internal carotid artery and their proximal branches, resulting in ischemic or hemorrhagic stroke with high rate of disability and even death. So far, available treatment strategies are quite limited, and novel intervention method is being explored. This review encapsulates current advances of moyamoya disease on the aspects of epidemiology, etiology, clinical features, imaging diagnosis and treatment. In addition, we also bring forward our conjecture, which needs to be testified by future research.

Takeuchi K, Shimizu K (1957) Hypoplasia of the bilateral internal carotid arteries. Brain Nerve 9:37–43

Scott RM, Smith ER (2009) Moyamoya disease and moyamoya syndrome. N Engl J Med 360:1226–1237PubMedCrossRef

Matsushima T, Inoue T, Natori Y, Fujii K, Fukui M, Hasuo K, Kuwabara Y (1994) Children with unilateral occlusion or stenosis of the ICA associated with surrounding moyamoya vessels--"unilateral" moyamoya disease. Acta Neurochir 131(3–4):196–202PubMedCrossRef

Goto Y, Yonekawa Y (1992) Worldwide distribution of moyamoya disease. Neurol Med Chir (Tokyo) 32(12):883–886CrossRef

Kuroda S, Houkin K (2008) Moyamojyya disease: current concepts and future perspectives. Lancet Neurol 7(11):1056–1066PubMedCrossRef

Ma Y, Zhao M, Zhang Q, Liu X, Zhang D, Wang S, Zhang Y, Li M, Zhao J (2017) Risk factors for epilepsy recurrence after revascularization in pediatric patients with moyamoya disease. J Stroke Cerebrovasc Dis 27(3):740–746PubMedCrossRef

Porras JL, Yang W, Xu R et al (2017) Effectiveness of ipsilateral stroke prevention between conservative management and indirect revascularization for moyamoya disease (MMD) in a North American cohort. World Neurosurg 110:e928–e936PubMedCrossRef

Qiao PG, Han C, Zuo ZW, Wang YT, Pfeuffer J, Duan L, Qian T, Li GJ (2017) Clinical assessment of cerebral hemodynamics in Moyamoya disease via multiple inversion time arterial spin labeling and dynamic susceptibility contrast-magnetic resonance imaging: a comparative study. J Neuroradiol 44(4):273–280PubMedCrossRef

Su P, Mao D, Liu P, Li Y, Pinho MC, Welch BG, Lu H (2017) Multiparametric estimation of brain hemodynamics with MR fingerprinting ASL. Magn Reson Med 78(5):1812–1823PubMedCrossRef

10.

Duan L, Wei L, Tian Y, Zhang Z, Hu P, Wei Q, Liu S, Zhang J, Wang Y, Li D, Yang W, Zong R, Xian P, Han C, Bao X, Zhao F, Feng J, Liu W, Cao W, Zhou G, Zhu C, Yu F, Yang W, Meng Y, Wang J, Chen X, Wang Y, Shen B, Zhao B, Wan J, Zhang F, Zhao G, Xu A, Zhang X, Liu J, Zuo X, Wang K (2018) Novel susceptibility loci for moyamoya disease revealed by a genome-wide association study. Stroke 49(1):11–18PubMedCrossRef

11.

Wakai K, Tamakoshi A, Ikezaki K et al (2008) Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke 39(1):42–47PubMedCrossRef

12.

Baba T, Houkin K, Kuroda S (2008) Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 79(8):900–904PubMedCrossRef

13.

Hoshino H, Izawa Y, Suzuki N (2012) Epidemiological features of moyamoya disease in Japan. Neurol Med Chir (Tokyo) 52(5):295–298

14.

Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, Kojima M, Lin Y, Ohno Y (1997) Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg 99(Suppl 2):S1–S5PubMedCrossRef

15.

Ikezaki K, Han DH, Kawano T, Inamura T, Fukui M (1997) Epidemiological survey of moyamoya disease in Korea. Clin Neurol Neurosurg 99(Suppl 2):S6–S10

16.

Ikezaki K, Han DH, Kawano T et al (1997) A clinical comparison of definite moyamoya disease between South Korea and Japan. Stroke 28(12):2513–2517PubMedCrossRef

17.

Ahn IM, Park DH, Hann HJ, Kim KH, Kim HJ, Ahn HS (2014) Incidence, prevalence, and survival of moyamoya disease in Korea: a nationwide, population-based study. Stroke 45(4):1090–1095PubMedCrossRef

18.

Kim T, Lee H, Bang JS, Kwon OK, Hwang G, Oh CW (2015) Epidemiology of moyamoya disease in Korea: based on National Health Insurance Service data. J Korean Neurosurg Soc 57(6):390–395PubMedPubMedCentralCrossRef

19.

Miao W, Zhao PL, Zhang YS, Liu HY, Chang Y, Ma J, Huang QJ, Lou ZX (2010) Epidemiological and clinical features of moyamoya disease in Nanjing, China. Clin Neurol Neurosurg 112(3):199–203PubMedCrossRef

20.

Duan L, Bao XY, Yang WZ, Shi WC, Li DS, Zhang ZS, Zong R, Han C, Zhao F, Feng J (2012) Moyamoya disease in China: its clinical features and outcomes. Stroke 43(1):56–60PubMedCrossRef

21.

Hung CC, Tu YK, Su CF, Lin LS, Shih CJ (1997) Epidemiological study of moyamoya disease in Taiwan. Clin Neurol Neurosurg 99(Suppl 2):S23–S25PubMedCrossRef

22.

Chen PC, Yang SH, Chien KL, Tsai IJ, Kuo MF (2014) Epidemiology of moyamoya disease in Taiwan: a nationwide population-based study. Stroke 45(5):1258–1263PubMedCrossRef

23.

Chiu D, Shedden P, Bratina P, Grotta JC (1998) Clinical features of moyamoya disease in the United States. Stroke 29(7):1347–1351PubMedCrossRef

24.

Kainth D, Chaudhry SA, Kainth H, Suri FK, Qureshi AI (2013) Epidemiological and clinical features of moyamoya disease in the USA. Neuroepidemiology 40(4):282–287PubMedCrossRef

25.

Wang Y, Zhao X, Liu L, Soo YOY, Pu Y, Pan Y, Wang Y, Zou X, Leung TWH, Cai Y, Bai Q, Wu Y, Wang C, Pan X, Luo B, Wong KSL, for the CICAS Study Group, Additional members of the CICAS study group are as follows:, Zhang X, Sun X, Yu L, Guo M, Ma Q, Xiao B, Zhang L, Zhang Z, Xu A, Li J, Lin J, Xing C, Xu Y, Zheng R, Han Z, Yuan X, Cui W, Zou Y, Yan H (2014) Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) study. Stroke 45(3):663–669

26.

Rafat N, Beck GC, Peña-Tapia PG et al (2009) Increased levels of circulating endothelial progenitor cells in patients with moyamoya disease. Stroke 40(2):432–438PubMedCrossRef

27.

Kim JH, Jung JH, Phi JH, Kang HS, Kim JE, Chae JH, Kim SJ, Kim YH, Kim YY, Cho BK, Wang KC, Kim SK (2010) Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease. J Neurosci Res 88(3):510–518PubMed

28.

Choi JW, Son SM, Mook-Jung I et al (2017) Mitochondrial abnormalities related to the dysfunction of circulating endothelial colony-forming cells in moyamoya disease. J Neurosurg 8:1–9

29.

Yoshihara T, Taguchi A, Matsuyama T, Shimizu Y, Kikuchi-Taura A, Soma T, Stern DM, Yoshikawa H, Kasahara Y, Moriwaki H, Nagatsuka K, Naritomi H (2008) Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels. J Cereb Blood Flow Metab 28(6):1086–1089PubMedCrossRef

30.

Jung KH, Chu K, Lee ST, Park HK, Kim DH, Kim JH, Bahn JJ, Song EC, Kim M, Lee SK, Roh JK (2008) Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease. J Cereb Blood Flow Metab 28(11):1795–1803PubMedCrossRef

31.

Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407(6801):242–248PubMedCrossRef

32.

Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, Wang KC, Cho BK, Kim SK (2010) Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry 81(6):673–678PubMedCrossRef

33.

Sakamoto S, Kiura Y, Yamasaki F, Shibukawa M, Ohba S, Shrestha P, Sugiyama K, Kurisu K (2008) Expression of vascular endothelial growth factor in dura mater of patients with moyamoya disease. Neurosurg Rev 31(1):77–81PubMedCrossRef

34.

van Setten GB (1995) Basic fibroblast growth factor in human saliva: detection and physiological implications. Laryngoscope 105(6):610–612PubMedCrossRef

35.

Takahashi A, Sawamura Y, Houkin K, Kamiyama H, Abe H (1993) The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci Lett 160(2):214–216PubMedCrossRef

36.

Yoshimoto T, Houkin K, Takahashi A, Abe H (1996) Angiogenic factors in moyamoya disease. Stroke 27(12):2160–2165PubMedCrossRef

37.

Morishita R, Sakaki M, Yamamoto K, Iguchi S, Aoki M, Yamasaki K, Matsumoto K, Nakamura T, Lawn R, Ogihara T, Kaneda Y (2002) Impairment of collateral formation in lipoprotein(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation 105(12):1491–1496PubMedCrossRef

38.

Nanba R, Kuroda S, Ishikawa T, Houkin K, Iwasaki Y (2004) Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke 35(12):2837–2842PubMedCrossRef

39.

Yamamoto M, Aoyagi M, Tajima S, Wachi H, Fukai N, Matsushima Y, Yamamoto K (1997) Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke 28(9):1733–1738PubMedCrossRef

40.

Hojo M, Hoshimaru M, Miyamoto S, Taki W, Nagata I, Asahi M, Matsuura N, Ishizaki R, Kikuchi H, Hashimoto N (1998) Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg 89(4):623–629PubMedCrossRef

41.

Bower RS, Mallory GW, Nwojo M, Kudva YC, Flemming KD, Meyer FB (2013) Moyamoya disease in a primarily white, midwestern US population: increased prevalence of autoimmune disease. Stroke 44(7):1997–1999PubMedCrossRef

42.

Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, Abe H, Inoue T, Ikezaki K, Matsushima T, Fukui M (2000) Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31(4):930–935PubMedCrossRef

43.

Inoue TK, Ikezaki K, Sasazuki T, Ono T, Kamikawaji N, Matsushima T, Fukui M (1997) DNA typing of HLA in the patients with moyamoya disease. Jpn J Hum Genet 42(4):507–515PubMedCrossRef

44.

Kraemer M, Horn PA, Roder C, Khan N, Diehl RR, Berlit P, Heinemann FM (2012) Analysis of human leucocyte antigen genes in Caucasian patients with idiopathic moyamoya angiopathy. Acta Neurochir 154(3):445–454PubMedCrossRef

45.

Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, Kanno J, Niihori T, Ono M, Ishii N, Owada Y, Fujimura M, Mashimo Y, Suzuki Y, Hata A, Tsuchiya S, Tominaga T, Matsubara Y, Kure S (2011) A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet 56(1):34–40PubMedCrossRef

46.

Liao X, Deng J, Dai W, Zhang T, Yan J (2017) Rare variants of RNF213 and moyamoya/non-moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review. Environ Health Prev Med 22(1):75PubMedPubMedCentralCrossRef

47.

Park YS, An HJ, Kim JO et al (2017) The role of RNF213 4810G>A and 4950G>A variants in patients with moyamoya disease in Korea. Int J Mol Sci 18(11):E2477PubMedCrossRef

48.

Wu Z, Jiang H, Zhang L, Xu X, Zhang X, Kang Z, Song D, Zhang J, Guan M, Gu Y (2012) Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One 7(10):e48179PubMedPubMedCentralCrossRef

49.

Dai D, Lu Q, Huang Q, Yang P, Hong B, Xu Y, Zhao W, Liu J, Li Q (2014) Serum miRNA signature in moyamoya disease. PLoS One 9(8):e102382PubMedPubMedCentralCrossRef

50.

Gao F, Yu L, Zhang D, Zhang Y, Wang R, Zhao J (2016) Long noncoding RNAs and their regulatory network: potential therapeutic targets for adult moyamoya disease. World Neurosurg 93:111–119PubMedCrossRef

51.

Zhao M, Gao F, Zhang D, Wang S, Zhang Y, Wang R, Zhao J (2017) Altered expression of circular RNAs in moyamoya disease. J Neurol Sci 381:25–31PubMedCrossRef

52.

Masuda J, Ogata J, Yutani C (1993) Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke 24(12):1960–1967PubMedCrossRef

53.

Lin R, Xie Z, Zhang J, Xu H, Su H, Tan X, Tian D, Su M (2012) Clinical and immunopathological features of Moyamoya disease. PLoS One 7(4):e36386PubMedPubMedCentralCrossRef

54.

Li H, Zhang ZS, Dong ZN, Ma MJ, Yang WZ, Han C, du MM, Liu YX, Yang H, Liu W, Duan L, Cao WC (2011) Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with moyamoya disease: a case-control study. Stroke 42(4):1138–1139PubMedCrossRef

55.

Fujimura M, Fujimura T, Kakizaki A, Sato-Maeda M, Niizuma K, Tomata Y, Aiba S, Tominaga T (2018) Increased serum production of soluble CD163 and CXCL5 in patients with moyamoya disease: involvement of intrinsic immune reaction in its pathogenesis. Brain Res 5(1679):39–44CrossRef

56.

Ni G, Liu W, Huang X, Zhu S, Yue X, Chen Z, Chen M, Liu X, Xu G (2011) Increased levels of circulating SDF-1alpha and CD34+ CXCR4+ cells in patients with moyamoya disease. Eur J Neurol 18(11):1304–1309PubMedCrossRef

57.

Weng L, Cao X, Han L, Zhao H, Qiu S, Yan Y, Wang X, Chen X, Zheng W, Xu X, Gao Y, Chen Y, Li J, Yang Y, Xu Y (2017) Association of increased Treg and Th17 with pathogenesis of moyamoya disease. Sci Rep 7(1):3071PubMedPubMedCentralCrossRef

58.

Kazumata K, Tha KK, Narita H, Kusumi I, Shichinohe H, Ito M, Nakayama N, Houkin K (2015) Chronic ischemia alters brain microstructural integrity and cognitive performance in adult moyamoya disease. Stroke 46(2):354–360PubMedCrossRef

59.

Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis) (2012) Neurol Med Chir (Tokyo) 52(5):245–266CrossRef

60.

Kim SK, Cho BK, Phi JH, Lee JY, Chae JH, Kim KJ, Hwang YS, Kim IO, Lee DS, Lee J, Wang KC (2010) Pediatric moyamoya disease: an analysis of 410 consecutive cases. Ann Neurol 68(1):92–101PubMedCrossRef

61.

Guey S, Tournier-Lasserve E, Hervé D, Kossorotoff M (2015) Moyamoya disease and syndromes: from genetics to clinical management. Appl Clin Genet 8:49–68PubMedPubMedCentral

62.

Lee JY, Choi YH, Cheon JE, Paeng JC, Ryu HW, Kim KJ, Phi JH, Wang KC, Cho BK, Chae JH, Kim SK (2014) Delayed posterior circulation insufficiency in pediatric moyamoya disease. J Neurol 261(12):2305–2313PubMedCrossRef

63.

Shi J, Meng R, Konakondla S, Ding Y, Duan Y, Wu D, Wang B, Luo Y, Ji X (2017) Cerebral watershed infarcts may be induced by hemodynamic changes in blood flow. Neurol Res 39(6):538–544PubMedCrossRef

64.

Zhao M, Deng X, Wang S et al (2017) Lacunar infarction in adult patients with moyamoya disease. Clin Neurol Neurosurg 164:81–86PubMedCrossRef

65.

Liu XJ, Zhang D, Wang S, Zhao YL, Teo M, Wang R, Cao Y, Ye X, Kang S, Zhao JZ (2015) Clinical features and long-term outcomes of moyamoya disease: a single-center experience with 528 cases in China. J Neurosurg 122(2):392–399PubMedCrossRef

66.

Nah HW, Kwon SU, Kang DW, Ahn JS, Kwun BD, Kim JS (2012) Moyamoya disease-related versus primary intracerebral hemorrhage: [corrected] location and outcomes are different. Stroke 43(7):1947–1950PubMedCrossRef

67.

Ge P, Zhang Q, Ye X, Liu X, Deng X, Li H, Wang R, Zhang Y, Zhang D, Cao Y, Wang S, Zhao J (2017) Clinical features of hemorrhagic moyamoya disease in China. World Neurosurg. 106:224–230PubMedCrossRef

68.

Funaki T, Takahashi JC, Houkin K, Kuroda S, Takeuchi S, Fujimura M, Tomata Y, Miyamoto S, JAM Trial Investigators (2018) High rebleeding risk associated with choroidal collateral vessels in hemorrhagic moyamoya disease: analysis of a nonsurgical cohort in the Japan Adult Moyamoya Trial. J Neurosurg:1–8

69.

Funaki T, Takahashi JC, Houkin K, Kuroda S, Takeuchi S, Fujimura M, Tomata Y, Miyamoto S, JAM Trial Investigators (2018) Angiographic features of hemorrhagic moyamoya disease with high recurrence risk: a supplementary analysis of the Japan adult Moyamoya trial. J Neurosurg 128(3):777–784PubMedCrossRef

70.

Kikuta K, Takagi Y, Nozaki K, Sawamoto N, Fukuyama H, Hashimoto N (2008) The presence of multiple microbleeds as a predictor of subsequent cerebral hemorrhage in patients with moyamoya disease. Neurosurgery 62(1):104–111PubMedCrossRef

71.

Kim JE, Jeon JS (2014) An update on the diagnosis and treatment of adult Moyamoya disease taking into consideration controversial issues. Neurol Res 36(5):407–416PubMedCrossRef

72.

Suzuki J, Kodama N (1971) Cerebrovascular “Moyamoya” disease. 2. Collateral routes to forebrain via ethmoid sinus and superior nasal meatus. Angiology 22(4):223–236PubMedCrossRef

73.

Kawano T, Ohmori Y, Kaku Y, Muta D, Uekawa K, Nakagawa T, Amadatsu T, Kasamo D, Shiraishi S, Kitajima M, Kuratsu JI (2016) Prolonged mean transit time detected by dynamic susceptibility contrast magnetic resonance imaging predicts cerebrovascular reserve impairment in patients with moyamoya disease. Cerebrovasc Dis 42(1–2):131–138PubMedCrossRef

74.

Qiao PG, Zuo ZW, Han C, Zhou J, Zhang HT, Duan L, Qian T, Li GJ (2017) Changes in hemodynamic response patterns in motor cortices measured by task-based functional magnetic resonance imaging in patients with moyamoya disease. J Comput Assist Tomogr 41(3):461–466PubMedCrossRef

75.

Kazumata K, Tha KK, Uchino H, Ito M, Nakayama N, Abumiya T (2017) Mapping altered brain connectivity and its clinical associations in adult moyamoya disease: a resting-state functional MRI study. PLoS One 12(8):e0182759PubMedPubMedCentralCrossRef

76.

Brinjikji W, Mossa-Basha M, Huston J, Rabinstein AA, Lanzino G, Lehman VT (2017) Intracranial vessel wall imaging for evaluation of steno-occlusive diseases and intracranial aneurysms. J Neuroradiol 44(2):123–134PubMedCrossRef

77.

Takagi Y, Hermanto Y, Takahashi JC, et al. (2016) Histopathological characteristics of distal middle cerebral artery in adult and pediatric patients with moyamoya disease. Neurol Med Chir (Tokyo) 15;56(6):345–349

78.

Kim YJ, Lee JK, Ahn SH, Kim BJ, Kang DW, Kim JS, Kwon SU (2016) Nonatheroscleotic isolated middle cerebral artery disease may be early manifestation of moyamoya disease. Stroke 47(9):2229–2235PubMedCrossRef

79.

Mossa-Basha M, de Havenon A, Becker KJ, Hallam DK, Levitt MR, Cohen WA, Hippe DS, Alexander MD, Tirschwell DL, Hatsukami T, Amlie-Lefond C, Yuan C (2016) Added value of vessel wall magnetic resonance imaging in the differentiation of moyamoya vasculopathies in a non-Asian cohort. Stroke 47(7):1782–1788PubMedPubMedCentralCrossRef

80.

Yu LB, He H, Zhao JZ, Wang R, Zhang Q, Shi ZY, Shao JS, Zhang D (2016) More precise imaging analysis and diagnosis of moyamoya disease and moyamoya syndrome using high-resolution magnetic resonance imaging. World Neurosurg. 96:252–260PubMedCrossRef

81.

Kim JM, Jung KH, Sohn CH, Park J, Moon J, Han MH, Roh JK (2013) High-resolution MR technique can distinguish moyamoya disease from atherosclerotic occlusion. Neurology 19;80(8):775–776

82.

Kim YJ, Lee DH, Kwon JY, Kang DW, Suh DC, Kim JS, Kwon SU (2013) High resolution MRI difference between moyamoya disease and intracranial atherosclerosis. Eur J Neurol 20(9):1311–1318PubMedCrossRef

83.

Yu LB, Zhang Q, Shi ZY, Wang MQ, Zhang D (2015) High-resolution magnetic resonance imaging of moyamoya disease. Chin Med J 128(23):3231–3237PubMedPubMedCentralCrossRef

84.

Oh BH, Moon HC, Baek HM, Lee YJ, Kim SW, Jeon YJ, Lee GS, Kim HR, Choi JH, Min KS, Lee MS, Kim YG, Kim DH, Kim WS, Park YS (2017) Comparison of 7T and 3T MRI in patients with moyamoya disease. Magn Reson Imaging 37:134–138PubMedCrossRef

85.

Kuroda S, Ishikawa T, Houkin K, Nanba R, Hokari M, Iwasaki Y (2005) Incidence and clinical features of disease progression in adult moyamoya disease. Stroke 36(10):2148–2153PubMedCrossRef

86.

Onozuka D, Hagihara A, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Toyoda K, Matsuda S, Suzuki A, Kataoka H, Nakamura F, Kamitani S, Nishimura A, Kurogi R, Sayama T, Iihara K, the J-ASPECT Study Collaborators (2016) Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study). BMJ Open 6(3):e009942PubMedPubMedCentralCrossRef

87.

Smith ER, Scott RM (2005) Surgical management of moyamoya syndrome. Skull Base 15(1):15–26PubMedPubMedCentralCrossRef

88.

Kobayashi H, Hayashi M, Handa Y, Kabuto M, Noguchi Y, Aradachi H (1991) EC-IC bypass for adult patients with moyamoya disease. Neurol Res 13(2):113–116PubMedCrossRef

89.

Iwama T, Hashimoto N, Tsukahara T, Miyake H (1997) Superficial temporal artery to anterior cerebral artery direct anastomosis in patients with moyamoya disease. Clin Neurol Neurosurg 99(Suppl 2):S134–S136PubMedCrossRef

90.

Hayashi T, Shirane R, Tominaga T (2009) Additional surgery for postoperative ischemic symptoms in patients with moyamoya disease: the effectiveness of occipital artery-posterior cerebral artery bypass with an indirect procedure: technical case report. Neurosurgery 64(1):E195–E196PubMedCrossRef

91.

Matsushima Y, Inaba Y (1984) Moyamoya disease in children and its surgical treatment. Introduction of a new surgical procedure and its follow-up angiograms. Childs Brain 11(3):155–170PubMed

92.

Takeuchi S, Tsuchida T, Kobayashi K, Fukuda M, Ishii R, Tanaka R, Ito J (1983) Treatment of moyamoya disease by temporal muscle graft ‘encephalo-myo-synangiosis’. Childs Brain 10(1):1–15PubMed

93.

Bang JS, Kwon OK, Kim JE, Kang HS, Park H, Cho SY, Oh CW (2012) Quantitative angiographic comparison with the OSIRIS program between the direct and indirect revascularization modalities in adult moyamoya disease. Neurosurgery 70(3):625–632PubMedCrossRef

94.

Kawaguchi T, Fujita S, Hosoda K, Shose Y, Hamano S, Iwakura M, Tamaki N (1996) Multiple burr-hole operation for adult moyamoya disease. J Neurosurg 84(3):468–476PubMedCrossRef

95.

Noshiro S, Mikami T, Komatsu K, Kanno A, Enatsu R, Yazawa S, Nagamine T, Matsuhashi M, Mikuni N (2016) Neuromodulatory role of revascularization surgery in moyamoya disease. World Neurosurg. 91:473–482PubMedCrossRef

96.

Rashad S, M2 F, K1 N et al (2016) Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management. Neurosurg Rev 39(4):615–623

97.

Gupta R, Moore M, J, Adeeb N et al (2016) Clinical presentation, progression, and treatment outcomes of moyamoya disease in the elderly. Acta Neurochir 158(12):2409–2414

98.

Zhang L, Xu K, Zhang Y, Wang X, Yu J (2015) Treatment strategies for aneurysms associated with moyamoya disease. Int J Med Sci 12(3):234–242PubMedPubMedCentralCrossRef

99.

Kuroda S, Kashiwazaki D, Hirata K, Shiga T, Houkin K, Tamaki N (2014) Effects of surgical revascularization on cerebral oxygen metabolism in patients with Moyamoya disease: an 15O-gas positron emission tomographic study. Stroke 45(9):2717–2721PubMedCrossRef

100.

Yamada S, Oki K, Itoh Y, Kuroda S, Houkin K, Tominaga T, Miyamoto S, Hashimoto N, Suzuki N, Research Committee on Spontaneous Occlusion of Circle of Willis (Moyamoya Disease) (2016) Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of research committee on moyamoya disease in Japan. J Stroke Cerebrovasc Dis 25(2):340–349PubMedCrossRef

101.

Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T, Nakagawara J, Takahashi JC, on behalf of the JAM Trial Investigators, Yamada K, Tomata Y, Fukui T, Fukuuchi Y, Ohmoto T, Kuwabara Y, Nagata I, Ono J, Machida T, Sakakibara R, Yamane K, Okita S, Iwama T, Kaku Y, Saito N, Fukuyama H, Houkin K, Kuroda S, Yabe I, Moriwaka F, Ogawa A, Ogasawara K, Yoshida K, Fujii K, Yamada M, Sato K, Akutsu T, Yamagata S, Takeuchi S, Hayashi K, Horie N, Yamada K, Osato T, Watanabe T, Honjo K, Sako K, Nakase H, Kawaguchi S, Nisimura F, Yamao J, Naritomi H, Inoue T, Abe H, Suzuki A, Ishikawa T, Akiyama Y, Suenaga T, Fujimura M, Nagahiro S, Uno M, Nishi K, Satomi J, Okada Y, Kawashima A, Yamaguchi K, Tsutsumi Y (2014) Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke 45(5):1415–1421PubMedCrossRef

102.

Ren B, Zhang ZS, Liu WW, Bao XY, Li DS, Han C, Xian P, Zhao F, Wang H, Wang H, Duan L (2016) Surgical outcomes following encephaloduroarteriosynangio-sis in adult moyamoya disease associated with type 2 diabetes. J Neurosurg 125(2):308–314PubMedCrossRef

103.

Cheung AH, Lam AK, Ho WW et al (2017) Surgical outcome for moyamoya disease—clinical and perfusion computed tomography correlation. World Neurosurg. 98:81–88PubMedCrossRef

104.

Ge P, Ye X, Zhang Q, et al. Encephaloduroateriosynangiosis versus conservative treatment for patients with moyamoya disease at late Suzuki stage. J Clin Neurosci. 2018; pii: S0967–5868(17)31689–2

105.

Kazumata K, Ito M, Tokairin K, Ito Y, Houkin K, Nakayama N, Kuroda S, Ishikawa T, Kamiyama H (2014) The frequency of postoperative stroke in moyamoya disease following combined revascularization: a single-university series and systematic review. J Neurosurg 121(2):432–440PubMedCrossRef

106.

Cho WS, Kim JE, Kim CH, Ban SP, Kang HS, Son YJ, Bang JS, Sohn CH, Paeng JC, Oh CW (2014) Long-term outcomes after combined revascularization surgery in adult moyamoya disease. Stroke 45(10):3025–3031PubMedCrossRef

Titel: Progress in moyamoya disease
verfasst von: Shuling Shang
Da Zhou
Jingyuan Ya
Sijie Li
Qi Yang
Yuchuan Ding
Xunming Ji
Ran Meng
Publikationsdatum: 18.06.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Neurosurgical Review / Ausgabe 2/2020
Print ISSN: 0344-5607
Elektronische ISSN: 1437-2320
DOI: https://doi.org/10.1007/s10143-018-0994-5

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Intradural “limited drill” technique of anterior clinoidectomy and optic canal unroofing for microneurosurgical management of ophthalmic segment and PCOM aneurysms—review of surgical results

Natural history of intraventricular meningiomas: systematic review

Anterior interhemispheric approach for clipping of subcallosal distal anterior cerebral artery aneurysms: case series and technical notes

How many patients require brain mapping in an adult neuro-oncology service?

Endoscope-assisted microsurgical evacuation versus external ventricular drainage for the treatment of cast intraventricular hemorrhage: results of a comparative series

Risk factors and control of seizures in 778 Chinese patients undergoing initial resection of supratentorial meningiomas

Update Chirurgie